Skip to main content

Articles

FDA Approvals, Introduction, Payers' Guide

FDA Approvals in 2017 Represent a 21-Year High

FDA Approvals, Payers' Guide

FDA Approvals of Brand-Name Prescription Drugs in 2017

Payers' Guide, FDA Approvals

Xermelo (Telotristat Ethyl), First-in-Class Tryptophan Hydroxylase Inhibitor, Approved for Carcinoid Syndrome Diarrhea

Payers' Guide, FDA Approvals

Vyxeos (Daunorubicin and Cytarabine) Liposomal Combination First Treatment Approved for Patients with High-Risk Acute Myeloid Leukemia

Payers' Guide, FDA Approvals

Tremfya (Guselkumab), First-in-Class IL-23 Blocker, Approved for the Treatment of Patients with Moderate-to-Severe Plaque Psoriasis

Payers' Guide, FDA Approvals

Simponi Aria (Golimumab), the Only Fully Human Anti–TNF-α Infused Therapy, Now Approved for Active Psoriatic Arthritis and for Active Ankylosing Spondylitis

Payers' Guide, FDA Approvals

Siliq (Brodalumab) a New IL-17RA Antagonist Approved for Moderate-to-Severe Plaque Psoriasis

Payers' Guide, FDA Approvals

Shingrix (Zoster Vaccine Recombinant) a New Vaccine Approved for Herpes Zoster Prevention in Older Adults

Payers' Guide, FDA Approvals

Nerlynx (Neratinib) First Extended Adjuvant Therapy Approved for HER2-Positive Breast Cancer

Payers' Guide, FDA Approvals

Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer

Page 72 of 244
Results 711 - 720 of 2434